COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2. (2023)
Attributed to:
saRNA SARS-CoV-2 vaccine
funded by
COVID
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.eclinm.2022.101823
PubMed Identifier: 36684396
Publication URI: http://europepmc.org/abstract/MED/36684396
Type: Journal Article/Review
Volume: 56
Parent Publication: EClinicalMedicine
ISSN: 2589-5370